Who are Ocriplasmin 125µg's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Prolyl Endopeptidase, C1 inhibitor (human) [C1 INH], Nafamostat Mesilate, Urinary Kallikrein, C1 Esterase Inhibitor (Human), Group III - Serratiopeptidase Group.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ocriplasmin-125-g.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Ocriplasmin 125µg — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Ocriplasmin 125µg (Ocriplasmin 125µg) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Serine protease. Area: Ophthalmology.

phase 3 Serine protease Fibronectin and laminin (extracellular matrix proteins) Ophthalmology Small molecule Live · refreshed every 30 min

Target snapshot

Ocriplasmin 125µg (Ocriplasmin 125µg) — ThromboGenics. Ocriplasmin is a recombinant microplasmin that enzymatically cleaves fibronectin and laminin in the vitreous to dissolve vitreous-retinal adhesions.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Ocriplasmin 125µg TARGET	Ocriplasmin 125µg	ThromboGenics	phase 3	Serine protease	Fibronectin and laminin (extracellular matrix proteins)
Prolyl Endopeptidase	Prolyl Endopeptidase	Dr. C. Bonorino Udaondo Gastroenterology Hospital	marketed	Serine protease / Enzyme	Prolyl endopeptidase (PEP)
C1 inhibitor (human) [C1 INH]	C1 inhibitor (human) [C1 INH]	Shire	marketed	Complement inhibitor / Serine protease inhibitor	C1s protease / Classical complement pathway
Nafamostat Mesilate	Nafamostat Mesilate	Chong Kun Dang Pharmaceutical	marketed	Serine protease inhibitor	Serine proteases (thrombin, factor Xa, kallikrein, trypsin)
Urinary Kallikrein	Urinary Kallikrein	Second Affiliated Hospital, School of Medicine, Zhejiang University	marketed	Serine protease / Kinin-kallikrein system activator	Kininogen (substrate); B1 and B2 bradykinin receptors (downstream)
C1 Esterase Inhibitor (Human)	C1 Esterase Inhibitor (Human)	Shire	marketed	Serine protease inhibitor; complement regulator	C1 esterase inhibitor (C1-INH); Factor XIIa; plasma kallikrein
Group III - Serratiopeptidase Group	Group III - Serratiopeptidase Group	Zahoor khan	phase 3	Serine protease enzyme	Non-structural proteins, fibrin, inflammatory mediators

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Serine protease class)

Curemark · 1 drug in this class
ThromboGenics · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Ocriplasmin 125µg — Competitive Intelligence Brief. https://druglandscape.com/ci/ocriplasmin-125-g. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab